IP Library › Granted Patent US 12,343,384
Granted Patent B2
US 12,343,384 · App. 17/261,866 · Granted Jul 1, 2025

Compositions for cosmetic and dermatological use

Inventor: Serge Cappello (Tremblay en France, FR)
Assignee: SEMIOCARE SAS
A61K38/40A61K8/35A61K8/44A61K8/492A61K8/64A61K8/986A61K9/0014A61K31/12A61K31/198A61K31/405A61K35/20A61K38/018A61P17/00A61Q19/08A61K2800/522
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,343,384
App. No.
17/261,866
Granted
Jul 1, 2025
Kind
B2
Abstract

The invention concerns a composition for cosmetic or dermatological use comprising an iron-binding glycoprotein and a casein hydrolysate, and optionally comprising colostrum, a precursor of nitric oxide, an antioxidant and serotonin or one of the precursors thereof.

Claims (48)

1. A composition for topical application comprising lactoferrin, α-casozepine, and carboxymethylcellulose gel, wherein the weight ratio of lactoferrin to α-casozepine is from 0.1 to 6.

2. The composition according to claim 1 , further comprising colostrum.

3. The composition according to claim 1 comprising, by weight of dry matter one or more components selected from the group consisting of:

from 2 to 30% by weight of dry matter, of actoferrin;

from 2 to 30% by weight of dry matter, of α-casozepine;

from 15 to 70% by weight of dry matter, of colostrum;

from 10 to 50% by weight of dry matter, of nitric oxide precursor;

from 2 to 30% by weight of dry matter, of antioxidant; and

from 2 to 30% by weight of dry matter, of serotonin or a precursor thereof.

4. The composition according to claim 1 comprising, by weight of dry matter one or more components selected from the group consisting of:

from 2 to 30% by weight of dry matter of lactoferrin;

from 2 to 30% by weight of dry matter of α-casozepine;

from 15 to 70% by weight of dry matter of colostrum;

from 10 to 50% by weight of dry matter of L-arginine;

from 2 to 30% by weight of dry matter of astaxanthin; and

from 2 to 30% by weight of dry matter of tryptophan.

5. The composition according to claim 1 , comprising by weight of dry matter:

from 15 to 20% of lactoferrin;

from 5 to 10% of α-casozepine;

from 25 to 45% of colostrum;

from 20 to 30% of L-arginine;

from 5 to 10% of astaxanthin; and

from 5 to 10% of tryptophan.

6. A method for cosmetic treatment of the skin, comprising topically applying to the skin the composition according to claim 1 .

7. The method according to claim 6 , wherein the cosmetic treatment of the skin is selected from the group consisting of: filling wrinkles, reducing under-eye bags, lightening under-eye dark circles, reducing age spots, increasing skin elasticity and attenuating stretch marks.

8. A method for treatment of a dermatological disease comprising administering the composition according to claim 1 to a patient in need thereof.

9. The method according to claim 8 , wherein the dermatological disease is selected from the group consisting of: skin atrophy, eczema and cheloids.

10. The composition according to claim 2 , wherein the colostrum is bovine colostrum.

11. The composition according to claim 1 , further comprising a precursor of nitric oxide.

12. The composition according to claim 11 , wherein the precursor of nitric oxide is L-arginine.

13. The composition according to claim 1 , further comprising an antioxidant.

14. The composition according to claim 13 , wherein the antioxidant is astaxanthin.

15. The composition according to claim 1 , further comprising serotonin or a precursor thereof.

16. The composition according to claim 15 , wherein the serotonin or precursor thereof is tryptophan.

17. The composition according to claim 1 comprising, by weight of dry matter one or more components selected from the group consisting of:

from 10 to 30% by weight of dry matter of actoferrin;

from 3 to 20% by weight of dry matter of α-casozepine;

from 20 to 50% by weight of dry matter of colostrum;

from 15 to 40% by weight of dry matter of nitric oxide precursor;

from 3 to 20% by weight of dry matter of antioxidant; and

from 3 to 20% by weight of dry matter of serotonin or a precursor thereof.

18. The composition according to claim 1 comprising, by weight of dry matter one or more components selected from the group consisting of:

from 10 to 30% by weight of dry matter of lactoferrin;

from 3 to 20% by weight of dry matter of α-casozepine;

from 20 to 50% by weight of dry matter of colostrum;

from 15 to 40% by weight of dry matter of L-arginine;

from 3 to 20% by weight of dry matter of astaxanthin; and

from 3 to 20% by weight of dry matter of tryptophan.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2022
From: CAPPELLO, SERGE
To: SEMIOCARE SAS
Reel/Frame 061197/0214 →
Priority Claims (1)
FR 1856756 · Jul 20, 2018 · national
Continuity (1)
Related Publication 20210290737A1 · Sep 23, 2021
References Cited (24)
US 5314873A · Tomita · 1994 [cited by examiner]
US 5750149A · Gobbi · 1998 [cited by examiner]
US 20080045909A1 · Fossel · 2008 [cited by examiner]
US 20080317684A1 · Spann-Wade · 2008 [cited by examiner]
US 20100092497A1 · Kanwar · 2010 [cited by examiner]
US 20100272763A1 · Nakamura · 2010 [cited by examiner]
US 20110312892A1 · Balandras · 2011 [cited by examiner]
US 20130089572A1 · Vanderhoof et al. · 2013 [cited by applicant]
CA 2580372A1 · 2006 [cited by applicant]
EP 1997477A1 · 2008 [cited by applicant]
JP H03220130A · 1991 [cited by applicant]
JP 2009221157A · 2009 [cited by examiner]
WO 9965329A2 · 1999 [cited by applicant]
WO 2004047566A1 · 2004 [cited by applicant]
WO 2006098625A1 · 2006 [cited by applicant]
WO WO2007000651A1 · 2007 [cited by examiner]
WO 2008056983A1 · 2008 [cited by applicant]
WO 2015125067A1 · 2015 [cited by applicant]
English translation of JP2009221157A. English translation from Global Dossier. Retrieved on Oct. 20, 2023. (Year: 2023). [cited by examiner]
International Search Report and Written Report, PCT/EP2019/069603, mailed Oct. 8, 2019. [cited by applicant]
Edriss et al. “Therapy of keloid and hypertrophic scars: a review” European Journal of Plastic Surgery, Springer, Berlin, DE, vol. 34, No. 6 Jul. 1, 2011 (Jul. 1, 2011), pp. 425-436 DOI:10.1007/S00238-011-0602-1ISSNI435… [cited by applicant]
Callen J et al. “A systematic review of the safety of topical therapies for atopic dermatisis” The British Journal of Dermatology Feb. 2007 vol. 156 No. 2 Feb. 2007 (Feb. 2007) pp. 203-221 ISSN 0007-0963. [cited by applicant]
European Office Action, EP19742048.2, mailed Apr. 4, 2022, 7 pages. [cited by applicant]
Miclo, L. et al. “Characterization of alph-casozepine, a tryptic peptide from bovine alphas 1-casein with benzodiazepine-like activity” The FASEB Journal, Federation of American Societies for Experimental Biology, US, v… [cited by applicant]